Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-301 in HER2 Expressing Gastric Cancer
NCT05771584Phase 2Active, not recruiting
- Sponsor
- Aston Sci
- Start
- Jul 2023
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of AST-301 in gastric cancer (GC) (2 arms), sponsored by Aston Sci. Primary endpoints: Number of participants with treatment-related adverse events at 20 weeks and Immunologic efficacy of AST-301 immunization at 52 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
AST-301
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05771584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771584.